The COVID-19 pandemic has led to many changes in how pharmaceutical companies develop vaccines.

Combatting Future Viral Threats with Vaccine Advances

More technologies and treatments are emerging for COVID-19—along with new variants.

What’s Next for COVID-19 Vaccines and Variants?

Partnerships formed during the COVID-19 pandemic have provided a platform for change in assay development and transfers.

Key Elements for Assay Transfer Success

Topic

Articles

Almac Sciences has been granted an award by the COVID-19 Therapeutics Accelerator for the development of an efficient and scalable production process for remdesivir.

Almac Group Receives Award from COVID-19 Therapeutics Accelerator to Produce Remdesivir

Moderna has reported that EMA's CHMP has started a rolling review of mRNA-1273—Moderna’s COVID-19 vaccine candidate.

EMA Starts Rolling Review of Moderna’s COVID-19 Vaccine Candidate

The agency’s safety monitoring plan outlines how information that emerges after the authorization of COVID-19 vaccines will be collected and reviewed.

EMA Issues Safety Monitoring Plan for COVID-19 Vaccines

Pfizer and BioNTech’s BNT162b2 shows efficacy of 95%; the companies plan to submit a request, within days, to FDA for an EUA.

Pfizer and BioNTech COVID-19 Vaccine Candidate Meets Endpoints and Achieves Safety Data Milestone 

Stephen Hahn promises disclosure of supporting scientific data used to issue EUAs.


FDA Commits to Transparency in EUA Reviews

The guidance was published in connection with a safety monitoring plan for COVID-19 vaccines.

EMA Publishes Risk Management Guidance for COVID-19 Vaccines

The event will be rescheduled for Oct. 19–21, 2021 at the Javits Center in New York City. 

INTERPHEX 2021 Rescheduled Due to COVID-19

Moderna’s COVID-19 vaccine candidate can be distributed using widely available vaccine delivery and storage infrastructure.

Moderna Announces Extended Stability Conditions for COVID-19 Vaccine Candidate

Moderna CEO Stéphane Bancel says the company will submit EUA data for its vaccine candidate, mRNA-1273, which has shown efficacy of 94.5% in the first analysis of Phase III clinical test results.










Moderna on Track to Submit Data for Emergency Use Approval for its COVID-19 Vaccine Candidate

FDA issued emergency use authorization for bamlanivimab for patients at risk for severe COVID-19.

COVID-19 Update

Combatting Future Viral Threats with Vaccine Advances

What’s Next for COVID-19 Vaccines and Variants?

Key Elements for Assay Transfer Success